Sei Investments Co. Has $75.57 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sei Investments Co. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 715,372 shares of the medical equipment provider’s stock after buying an additional 18,433 shares during the quarter. Sei Investments Co. owned approximately 0.36% of Zimmer Biomet worth $75,565,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Dunhill Financial LLC boosted its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the last quarter. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the 4th quarter valued at $25,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet during the 3rd quarter valued at $35,000. Kentucky Trust Co acquired a new stake in Zimmer Biomet during the 4th quarter valued at $39,000. Finally, OFI Invest Asset Management acquired a new stake in Zimmer Biomet during the 4th quarter valued at $40,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.95% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several research reports. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Stifel Nicolaus raised their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Truist Financial reaffirmed a “hold” rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Raymond James lowered their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $110.79 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The business’s 50-day moving average price is $106.74 and its two-hundred day moving average price is $106.86. The stock has a market cap of $22.05 billion, a PE ratio of 24.90, a P/E/G ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the firm earned $2.20 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.